Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse

Diabetes

Volumn 59, Issue 8, 2010, Pages 2043-2054

  Reiniger, Nina ^a   Lau, Kai ^b   McCalla, Daren ^a   Eby, Bonnie ^b   Cheng, Bin ^a   Lu, Yan ^a   Qu, Wu ^a   Quadri, Nosirudeen ^a   Ananthakrishnan, Radha ^a   Furmansky, Maryana ^a   Rosario, Rosa ^a   Song, Fei ^a   Rai, Vivek ^a   Weinberg, Alan ^a   Friedman, Richard ^a   Ramasamy, Ravichandran ^a   D'Agati, Vivette ^a   Schmidt, Ann Marie ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; HEMOGLOBIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; INULIN CLEARANCE; KIDNEY PLASMA FLOW; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RENAL PROTECTION; TRANSMISSION ELECTRON MICROSCOPY; URINE FLOW RATE;

ANIMALS; BLOOD GLUCOSE; CHICKENS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; GENE DELETION; GLOMERULAR MESANGIUM; HEMOGLOBIN A, GLYCOSYLATED; KIDNEY; KIDNEY FAILURE; MICE; MICE, INBRED STRAINS; PYRUVALDEHYDE; RECEPTORS, IMMUNOLOGIC;

EID: 77955375901     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-1766     Document Type: Article

References (37)

1. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4:1025-1031 (Pubitemid 28417334)
2. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000;11:1656-1666
3. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, Schmidt AM. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003;162:1123-1137
4. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108:261-268 (Pubitemid 32656250)
5. Myint KM, Yamamoto Y, Doi T, Kato I, Harashima A, Yonekura H, Watanabe T, Shinohara H, Takeuchi M, Tsuneyama K, Hashimoto N, Asano M, Takasawa S, Okamoto H, Yamamoto H. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 2006;55:2510-2522 (Pubitemid 44871151)
6. Jensen LJ, Denner L, Schrijvers BF, Tilton RG, Rasch R, Flyvbjerg A. Renal effects of a neutralising RAGE-antibody in long-term streptozotocindiabetic mice. J Endocrinol 2006;188:493-501
7. Flyvbjerg A, Denner L, Schrijvers BF, Tilton RG, Mogensen TH, Paludan SR, Rasch R. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 2004;53:166-172 (Pubitemid 38044711)
8. Epstein PN, Overbeek PA, Means AR. Calmodulin-induced early-onset diabetes in transgenic mice. Cell 1989;58:1067-1073
9. Zheng S, Noonan WT, Metreveli NS, Coventry S, Kralik PM, Carlson EC, Epstein PN. Development of late-stage diabetic nephropathy in OVE26 diabetic mice. Diabetes 2004;53:3248-3257 (Pubitemid 39564502)
10. Powell DW, Bertram CC, Cummins TD, Barati MT, Zheng S, Epstein PN, Klein JB. Renal tubulointerstitial fibrosis in OVE26 type 1 diabetic mice. Nephron Exp Nephrol 2009;111:e11-e19
11. Yuzawa Y, Niki I, Kosugi T, Maruyama S, Yoshida F, Takeda M, Tagawa Y, Kaneko Y, Kimura T, Kato N, Yamamoto J, Sato W, Nakagawa T, Matsuo S. Overexpression of calmodulin in pancreatic beta cells induces diabetic nephropathy. J Am Soc Nephrol 2008;19:1701-1711
12. Kutz SM, Hordines J, McKeown-Longo PJ, Higgins PJ. TGF-beta1-induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. J Cell Sci 2001;114:3905-3914 (Pubitemid 33094705)
13. Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, Noda M, Wang W, Kawano Y, Collins A, Hsueh WA. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 2005;67:1297-1307 (Pubitemid 40463106)
14. Baricos WH, Cortez SL, el-Dahr SS, Schnaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 1995;47:1039-1047
15. Iglesias-de la Cruz MC, Ziyadeh FN, Isono M, Kouahou M, Han DC, Kalluri R, Mundel P, Chen S. Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 2002;62:901-913 (Pubitemid 35316719)
16. Mulder KM. Role of Ras and Mapks in TGFbeta signaling. Cytokine Growth Factor Rev 2000;11:23-35
17. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425:577-584 (Pubitemid 37280136)
18. Peng F, Wu D, Gao B, Ingram AJ, Zhang B, Chorneyko K, McKenzie R, Krepinsky JC. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 2008;57:1683-1692
19. Gojo A, Utsunomiya K, Taniguchi K, Yokota T, Ishizawa S, Kanazawa Y, Kurata H, Tajima N. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol 2007;568:242-247 (Pubitemid 46976901)
20. Bu DX, Rai V, Shen X, Rosario R, Lu Y, D'Agati V, Yan SF, Friedman RA, Nuglozeh E, Schmidt AM. Activation of the ROCK1 branch of the transforming growth factor-{beta} pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ Res 2010;106:1040-1051
21. Breyer MD. Stacking the deck for drug discovery in diabetic nephropathy: in search of an animal model. J Am Soc Nephrol 2008;19:1623-1624
22. Teiken JM, Audettey JL, Laturnus DI, Zheng S, Epstein PN, Carlson EC. Podocyte loss in aging OVE26 diabetic mice. Anat Rec (Hoboken) 2008;291:114-121
23. Breyer MD, Böttinger E, Brosius FC 3rd, Coffman TM, Harris RC, Heilig CW, Sharma K, AMDCC. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005;16:27-45 (Pubitemid 43073154)
24. Dunn SR, Qi Z, Bottinger EP, Breyer MD, Sharma K. Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int 2004;65:1959-1967 (Pubitemid 38591050)
25. Gaspari F, Perico N, Remuzzi G. Measurement of glomerular filtration rate. Kidney Int Suppl 1997;63:S151-S154
26. Ziyadeh FN. The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 1993;22:736-744
27. Miyoshi H, Taguchi T, Sugiura M, Takeuchi M, Yanagisawa K, Watanabe Y, Miwa I, Makita Z, Koike T. Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephropathy in mice. Horm Metab Res 2002;34:371-377
28. Peppa M, Brem H, Cai W, Zhang JG, Basgen J, Li Z, Vlassara H, Uribarri J. Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). Am J Nephrol 2006;26:430-436 (Pubitemid 44971733)
29. Ellis EN, Good BH. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 1991;40:1016-1019
30. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991;40:1328-1334
31. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 1994;91:11704-11708 (Pubitemid 24356413)
32. Thornalley PJ. The glyoxalase system in health and disease. Mol Aspects Med 1993;14:287-371
33. Collins SJ, Alexander SL, Lopez-Guisa JM, Cai X, Maruvada R, Chua SC, Zhang G, Okamura DM, Matsuo S, Eddy AA. Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice. Nephron Exp Nephrol 2006;104:e23-e34 (Pubitemid 44238888)
34. Lassila M, Fukami K, Jandeleit-Dahm K, Semple T, Carmeliet P, Cooper ME, Kitching AR. Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease. Diabetologia 2007;50:1315-1326 (Pubitemid 46701559)
35. Berrou J, Tostivint I, Verrecchia F, Berthier C, Boulanger E, Mauviel A, Marti HP, Wautier MP, Wautier JL, Rondeau E, Hertig A. Advanced glycation end products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells. Int J Mol Med 2009;23:513-520
36. Wilkinson-Berka JL, Kelly DJ, Koerner SM, Jaworski K, Davis B, Thallas V, Cooper ME. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes 2002;51:3283-3289 (Pubitemid 35246975)
37. Thomas MC, Tikellis C, Burns WM, Bialkowski K, Cao Z, Coughlan MT, Jandeleit-Dahm K, Cooper ME, Forbes JM. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005;16:2976-2984 (Pubitemid 44743495)